false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - The Car ...
Lipid Management in Kidney Diseases: What's New, W ...
Lipid Management in Kidney Diseases: What's New, What's Next?
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Professor Erin Mekos reviewed LDL cholesterol management in chronic kidney disease (CKD). CKD creates an atherogenic lipid profile, including elevated triglycerides and lipoprotein(a), impaired HDL function, and more small, dense LDL particles. Because cardiovascular risk is high, statins remain foundational; guidelines recommend statin therapy for people with stage 3 or higher CKD regardless of their calculated 10-year risk. Ezetimibe is a useful add-on, while statin choice and dosing should account for kidney function. Evidence for starting statins in dialysis patients is less clear, so decisions should be individualized.<br /><br />Newer guidelines emphasize treating earlier and targeting lower LDL levels. Many patients with CKD will need combination therapy to reach their goals. Options include ezetimibe, bempedoic acid, PCSK9 monoclonal antibodies, inclisiran, and newer oral PCSK9 inhibitors. Trials show that LDL lowering reduces cardiovascular events in CKD, with benefits broadly proportional to the degree of LDL reduction. Measuring lipoprotein(a) at least once is also recommended; although specific treatments are still under study, elevated levels identify risk and support intensifying other preventive measures.<br /><br />Mekos concluded that clinicians now have more treatment options and should use them to lower LDL earlier and sustain reductions over time.
Asset Caption
Erin D. Michos, MD
Meta Tag
Speaker
Erin D. Michos
Keywords
CKD
LDL cholesterol
statins
ezetimibe
PCSK9 inhibitors
lipoprotein(a)
cardiovascular risk
×
Please select your language
1
English